CMCaitlin R. McEntee

Caitlin R. McEntee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caitlin R. McEntee has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16

    by Spencer E. Moffitt, Anubhuti Srivastava, Naviya Schuster-Little, Caitlin R. McEntee, Jane C. March, Chien-Wei Wang, Danielle R. Dotson, Holly V. Goodson, Rebecca J. Whelan

    Measurements of the peptide epitope CA125 are crucial in ovarian cancer care. Despite its value as a tool in disease management, CA125 is an imperfect biomarker, with rates of false positive and false negative response that preclude its use as a screening tool in the general population. The monoclonal antibodies that perform capture and recognition in the CA125 test-OC125 and M11-were developed using complex targets as immunogens and recognize epitopes that have been located on mucin16 (MUC16) but otherwise remain undefined at the molecular level. We hypothesized that new antibodies recognizing MUC16 peptides of known sequence could enable the development of assay platforms that overcome the limitations of the current CA125 test. Here, we report the development and characterization of three sets of polyclonal antibodies that recognize known MUC16 peptides. Peptides that appear several times within MUC16's highly conserved tandem repeat region were used to immunize two sets of rabbits. Affinity-isolated antibodies were characterized by enzyme-linked immunosorbent assay (ELISA) and Western blot. All three peptides were successful antigens, as indicated by the ability of the resulting polyclonal antibodies to bind individually expressed proteins from the MUC16 tandem repeat region. In particular, the polyclonal antibodies raised against peptide 2 (ELGPYTLDRNSLYV) bound to all tandem repeats tested. Peptide 2 antibodies were able to detect intact MUC16 from ovarian cancer cells in a surface plasmon resonance (SPR) assay. In flow cytometry experiments, peptide 2 antibodies bind to MUC16-positive cells (OVCAR3) and do not bind to MUC16-negative cells (OVCAR8). The binding pattern of these polyclonal antibodies opens the possibility of developing new monoclonal antibodies recognizing known epitopes within the tandem repeat region. These reagents may eventually complement or replace the monoclonal antibodies used in the current clinical CA125 test.

  • Polyclonal antibodies targeting defined epitopes on cancer biomarker MUC16 (Dataset)

    by Spencer E. Moffitt, Anubhuti Srivastava, Naviya Schuster-Little, Caitlin McEntee, Jane March, Chien-Wei Wang, Danielle R. Dotson, Holly Goodson, Rebecca Whelan

  • Open Access

    Characterization of M11-like and OC125-like Monoclonal Antibody Binding to CA125 Tandem Repeats

    by Trisha Nair, Caitlin R. McEntee, Chien-Wei Wang, Anubhuti Srivastava, Jane C. March, Eliza K. Hanson, Rebecca J. Whelan

    The CA125 epitope within the MUC16 tandem repeat region is detected via the CA125 II test for ovarian cancer surveillance. This test utilizes the M11 and OC125 antibodies. A revised model of MUC16 with 19 tandem repeats has recently been identified, including splice variants that exclude entire repeats. Additionally, OC125 has exhibited gaps in coverage of the tandem repeat region. To identify antibodies that bind more repeats and are suitable for spliceoform detection, more antibodies must be characterized using the revised model. This study characterized the binding of two M11-like and two OC125-like antibodies against the updated tandem repeat numbering system. 16 individual tandem repeats were expressed and purified. Binding interactions between each of the antibodies and recombinant repeats were examined by indirect enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR). The M11-like antibodies displayed different binding patterns when compared to each other, while the two OC125-like antibodies exhibited similar binding patterns. M11-like clone M77161 bound to all 16 repeats tested, indicating that it may be suitable for accurate detection of CA125. These findings demonstrate how different antibodies vary in their binding to CA125, contributing to ongoing development of improved clinical and research tools for ovarian cancer.


  • Open Access

    Mapping the Binding Sites of CA125-Specific Antibodies on a Revised Molecular Model of MUC16

    by Chien-Wei Wang, Anubhuti Srivastava, Eliza K. Hanson, Caitlin R. McEntee, Trisha Nair, Jane C. March, Rebecca J. Whelan

    Background: The ovarian cancer biomarker CA125 is a peptide epitope found in multiple tandem repeat domains of the mucin MUC16. Although efforts have been undertaken to characterize the interaction between CA125 and its clinically used antibodies, the molecular nature of the CA125 epitope(s) remains undefined. A recent revision of the molecular model of MUC16 provides an opportunity to fully characterize the binding between CA125-specific antibodies and the tandem repeat region of MUC16. Objectives: The objective of this study was to characterize the binding between CA125 antibodies and expressed tandem repeat proteins from MUC16 as part of a longer-term effort to identify the CA125 epitopes with amino-acid-level precision. Methods: Sixteen MUC16 tandem repeat proteins were expressed and purified. Protein expression was confirmed with high-resolution mass spectrometry. The binding interaction of each tandem repeat protein with four CA125-antibodies—the two used in the clinical test (OC125 and M11) and two clones defined as OC125-like and M11-like—was measured using indirect enzyme-linked immunosorbent assay (ELISA) and localized surface plasmon resonance (SPR). Results: Whereas M11 was found by ELISA to bind to all 16 tandem repeat proteins tested, OC125 does not bind to 5 of the 16 repeats. The recognition pattern of the antibodies was largely in agreement between ELISA and SPR, and cases in which binding is observed in ELISA but not in SPR can be attributed to insufficient contact time in SPR analysis. Conclusions: It can be inferred that the M11 epitope is present on all tandem repeats tested, whereas the OC125 epitope is present on fewer tandem repeats.